Wednesday, July 8, 2026

pharma · T2DM (Type 2 Diabetes Mellitus) · Type 2 Diabetes Mellitus · ORMP

Oramed Pharmaceuticals

Oramed Pharmaceuticals is a pharma organization headquartered in Jerusalem, USA. It trades on NYSE under ticker ORMP. Primary therapeutic focus areas include T2DM (Type 2 Diabetes Mellitus), Type 2 Diabetes Mellitus, Typ

20 Mamilla Avenue, 3rd Floor, Jerusalem, 9414904, IL HQ
2006 Founded
16 Employees
Public company Type
ORMP · NYSE Ticker
Company details
Status
Public
HQ
20 Mamilla Avenue, 3rd Floor, Jerusalem, 9414904, IL
Founded
2006
Employees
16
Programs
14
Drugs
8
Patents
10
Clinical program

ORMD 0801

Phase 2 · small molecule · Brittle Type I Diabetes Mellitus

ORMD 0801 for Brittle Type I Diabetes Mellitus is a Phase 2 program (small_molecule) at ORAMED PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).

← All ORAMED PHARMACEUTICALS INC. projects Phase 2 small molecule completed

Internal code 0566-08-HMO-CTIL

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ORAMED PHARMACEUTICALS INC.
Phase
Phase 2
Modality
small_molecule
Indication
Brittle Type I Diabetes Mellitus
Status
completed
Trials
1

Clinical trials